Arrowhead Pharmaceuticals
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Arrowhead Pharmaceuticals
- Company name
- Arrowhead Pharmaceuticals
- Organisation type
- Industry
- Registered legal name
- Arrowhead Pharmaceuticals, Inc.
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- Website
- https://arrowheadpharma.com/
- SEC filer number (CIK)
- 0000879407
- Legal Entity Identifier (LEI)
- 549300O3CSB8T7OZ3D66
- Wikidata ID
- Q113530745
Related records
Trials (51)
- A First-In-Human Study of ARO-033 in Adult Participants
- A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
- A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection
- A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
- A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome
- A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
- A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers
- A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)
- A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)
- Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection
- Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
- Safety and Tolerability Study of ARC-520 in Healthy Volunteers
- Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels
- Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
- Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
- Study of ARC-520 in Patient With Chronic Hepatitis B Virus
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)